Christoph A Plass from 90 Winthrop Rd, Columbus, OH 43214, age 63, Phone: 6142687862

Detection Of Methylated Cpg Rich Sequences Diagnostic For Malignant Cells
view source
US Patent:

20050158731, Jul 21, 2005
Filed:

May 10, 2004
Appl. No.:

10/842072
Inventors:

Christoph Plass - Columbus OH, US
Assignee:

The Ohio State University Research Foundation - Columbus OH
International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50
C12P019/34
US Classification:

435006000, 435091200, 204450000, 702020000
Abstract:

The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differentially methylated in cancer cells as compared to normal cells.

Detection Of Methylated Cpg Rich Sequences Diagnostic For Malignant Cells
view source
US Patent:

20070259364, Nov 8, 2007
Filed:

May 1, 2007
Appl. No.:

11/742663
Inventors:

Christoph Plass - Columbus OH, US
Assignee:

The Ohio State University Research Foundation - Columbus OH
International Classification:

C12Q 1/68
US Classification:

435006000
Abstract:

The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differentially methylated in cancer cells as compared to normal cells.

Death Associated Protein Kinase 1 (Dapk1) And Uses Thereof For The Treatment Of Chronic Lympocytic Leukemia
view source
US Patent:

20100184037, Jul 22, 2010
Filed:

Feb 28, 2008
Appl. No.:

12/529214
Inventors:

Christoph Plass - Columbus OH, US
Albert de la Chapelle - Delaware OH, US
Assignee:

THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH
International Classification:

C12Q 1/68
C12N 9/12
C07H 21/04
US Classification:

435 6, 536 235, 435194, 536 241, 536 231
Abstract:

A method for determining susceptibility to chronic lymphocytic leukemia in a subject includes determining a loss or reduced expression of death associated protein kinase 1 (DAPK1) or fragments or functional equivalents thereof.

Detection Of Methylated Cpg Rich Sequences Diagnostic For Malignant Cells
view source
US Patent:

6893820, May 17, 2005
Filed:

Jan 31, 2001
Appl. No.:

09/775398
Inventors:

Christoph Plass - Columbus OH, US
Assignee:

The Ohio State University Research Foundation - Columbus OH
International Classification:

C12Q001/68
US Classification:

435 6, 435 912
Abstract:

The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differentially methylated in cancer cells as compared to normal cells.

Christoph A Plass